MAPK3 and non-small cell lung carcinoma: confirmed the role of membrane chol in the resistance of non-small cell lung cancer cells to tyrosine kinase inhibitor as chol depletion reversibly enhances the gefitinib inhibition of EGFR, Akt-1, MEK1/2, and ERK1/2 phosphorylation (Chen et al., 2018).